anidulafungin has been researched along with toremifene in 2 studies
| Studies (anidulafungin) | Trials (anidulafungin) | Recent Studies (post-2010) (anidulafungin) | Studies (toremifene) | Trials (toremifene) | Recent Studies (post-2010) (toremifene) |
|---|---|---|---|---|---|
| 568 | 33 | 331 | 602 | 109 | 133 |
| Protein | Taxonomy | anidulafungin (IC50) | toremifene (IC50) |
|---|---|---|---|
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 3.58 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Byun, SY; Choi, I; Jeon, S; Kim, S; Ko, M; Lee, J; Park, S; Shum, D | 1 |
1 review(s) available for anidulafungin and toremifene
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for anidulafungin and toremifene
| Article | Year |
|---|---|
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Niclosamide; Pandemics; Pneumonia, Viral; Pregnenediones; SARS-CoV-2; Vero Cells | 2020 |